Correction to: Blood Cancer Journal (2015) 5, e306; doi:10.1038/bcj.2015.32; published online 17 April 2015
Since the publication of this paper, the authors have noticed an error in the title. It should read ‘The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma and their uses in immunotherapies’.
This paper has now been corrected.
Additional information
The online version of the original article can be found at 10.1038/bcj.2015.32
Rights and permissions
About this article
Cite this article
Dosani, T., Carlsten, M., Maric, I. et al. Erratum: The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer Journal 5, e321 (2015). https://doi.org/10.1038/bcj.2015.49
Published:
Issue Date:
DOI: https://doi.org/10.1038/bcj.2015.49
This article is cited by
-
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
Journal of Hematology & Oncology (2022)
-
Microparticles and PD1 interplay added a prognostic impact in treatment outcomes of patients with multiple myeloma
Scientific Reports (2021)
-
Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma
European Journal of Nuclear Medicine and Molecular Imaging (2021)
-
Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies
Blood Cancer Journal (2019)
-
Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome
Annals of Hematology (2019)